Publications by Julie K. Lappas

< back to bio

Michigan Sues PBMs for Alleged Anticompetitive Conduct Impacting Independent Pharmacies

[05/21/25]

FTC Releases Second Interim Staff Report on Pharmacy Benefit Managers

[01/29/25]

Pressure on PBMs Intensifies as FTC Targets Top PBMs Over Insulin Rebates

[09/30/24]

CMS Rule on Agent Broker Compensation Paused by Texas Federal Court

[08/01/24]

Alabama’s Supreme Court Rules that Frozen Embryos Are Children Under State Law

[03/05/24]

Quoted in "10th Circ.'s Okla. PBM Ruling Could Curtail State Regulation," Law360, August 2023

[08/18/2023]

Proposed CMS Rule Targets PBM Price Transparency for Medicaid Managed Care Organizations

[06/23/23]

Quoted in "Can New Indiana Law Lower Drug Costs? Answer Is as Clear as Mud," IBJ, May 2023.

[05/19/2023]

CMS Updates Definition of Marketing for Medicare Advantage and Part D Plans: What Does this Mean for Plans?

[05/16/23]

Quoted in "Congress Poised To Act Amid Explosion of State PBM Laws," Law360, May 2023

[05/05/2023]

Quoted in "FTC Reveals PBM Investigation, Issues Policy Statement Targeting Rebates," AIS Health, July 2022.

[07/14/2022]

FTC Launches Inquiry into Pharmacy Benefit Managers: Is This Time Different?

[06/15/22]

Quoted in "What To Watch As Push To Rein In PBMs Advances," Law360, June 2022.

[06/10/2022]

Quoted in "High Court's PBM Ruling Spurred State Lawmakers To Action," Law360, April 2022.

[04/01/2022]

Winning the COVID-19 Vaccine Lottery: OIG Weighs in on Anti-Kickback Implications of COVID-19 Vaccine Incentive Programs

[07/07/21]

Open the Floodgates: U.S. Supreme Court Decides ERISA Does Not Preempt Arkansas State Law Regulating PBMs

[12/23/20]

Recent Government Actions Against Pharma Manufacturers Highlight Risks with Donations to Patient Assistance Funds

[12/22/20]

OIG Finalizes Controversial Rule Updating AKS Discount Safe Harbor Applicable to Prescription Drug Rebates

[12/21/20]

CMS Announces Geographic Direct Contracting Model

[12/14/20]

Pulling Back the Curtain: Final Rule Requires Payors to Disclose Rates

[12/02/20]

Pharmacists’ Expanded Authority to Administer Childhood Vaccines: What to Know

[10/06/20]

What’s in YOUR Cannabidiol Product Claim? FDA and FTC Want to Know

[10/24/19]

No Surprise Here…the Debate Continues on Surprise Billing

[08/28/19]

Additional Telehealth Benefits Coming to Medicare Advantage in 2020

[07/12/19]

CMS Updates Preclusion List Requirements for Medicare Advantage and Part D

[05/10/19]

"CMS Preclusion List Now in Effect," State Bar of Wisconsin, April 2019.

[04/10/2019]

Claims Denials Start April 1: What You Should Know About CMS’s New Preclusion List

[02/15/19]

Discount Disruption: PBM Rebate Protection May Be Removed, New Safe Harbors Combat Increasing Drug Costs

[02/01/19]

FDA Clarifies Position on CBD After Passage of 2018 Farm Bill

[01/18/19]

CMS Proposes to Require Manufacturers to Disclose Drug Prices in TV Ads

[11/21/18]

CMS Proposes Major Change to Medicare Part B Drug Payment System Introducing International Pricing Index Model

[11/09/18]

DOJ Approves Merger Between Cigna and Express Scripts, Paving the Way for Increased Vertical Integration Between Payers and PBMs

[10/04/18]

CMS Allows Medicare Advantage Plans to Implement Step Therapy for Part B Drugs – Will It Really Lower Drug Costs or Simply Increase Administrative Burdens?

[09/19/18]

CMS Removes Compliance Training Requirements for Downstream Providers Under Medicare Advantage and Part D

[07/05/18]

CMS Announces New Opioid Safety Measures for Part D Plan Sponsors: What Is Really Going On?

[05/23/18]

The Wave of PBM and Insurer Integration Continues as Cigna and Express Scripts Announce a Merger of Their Own

[03/16/18]

OIG Approves Pharmaceutical Manufacturer’s Replacement Program for Spoiled Biologics

[09/06/17]

New Indiana Law Imposes a Seven-Day Limit on Opioid Prescriptions

[06/21/17]

Prescriber Enrollment Requirements for Part D Prescriptions: Enforcement to Begin in Early 2017

[04/19/17]

Pharmacy Fraud and Abuse: Operationalizing the New OIG Final Rule in an Integrated Care Environment

[01/04/17]

OIG Approves Beneficiary Discounts and Premium Credits for Medigap Plan Using Preferred Hospital Networks

[12/20/16]

Efforts to Enhance Prescription Drug Pricing Transparency Gaining Traction: Implications for Pharmacy Stakeholders

[11/30/16]

OIG Issues Favorable Advisory Opinion on Prescription Drug Discount Program

[08/11/16]

Prescription Drug Compounding Practices for Hospitals, Pharmacies and Outsourcing Facilities – New FDA Draft Guidance Released

[04/20/16]

CMS Clarifies Compliance Training Requirements Applicable to Providers Under the Medicare Advantage and Part D Programs

[03/04/16]

OIG Issues Favorable Opinion on Preventive Care Program Incentives

[02/25/15]

OIG Warns That Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs

[10/21/14]

OIG Scrutinizes Specialty Pharmacy Arrangement in Unfavorable Advisory Opinion

[08/26/14]

OIG Updates Guidance on Prescription Drug Patient Assistance Programs

[06/25/14]

CMS Withdraws Controversial Changes to Medicare Part D

[03/25/14]

Patients to Have Direct Access to Laboratory Test Results

[02/12/14]